Study to investigate the benefit-risk ratio of treatment of relapsing-remitting multiple sclerosis (RRMS) by Natalizumab compared against fingolimod, interferon-β, and no treatment across progressive multifocal leukoencephalopathy risk sub-groups.
Phase of Trial: Phase IV
Latest Information Update: 17 Dec 2015
At a glance
- Drugs Natalizumab (Primary) ; Fingolimod; Interferon beta
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 17 Dec 2015 New trial record